Professor of Critical Care Medicine
Manu Shankar-Hari is a Professor of Critical Care Medicine and leads a translational research group within the School of Immunology and Microbial Sciences at King’s College London. He was appointed as a consultant physician in Intensive Care Medicine at Guy’s and St Thomas’ Hospital NHS Foundation Trust in 2009. He was awarded the prestigious NIHR Clinician Scientist Award in 2016 and was recognised for his contributions to sepsis research with the ANZICS Intensive Care Global rising star award in 2017 and International Sepsis Forum Lowry Fink Fellowship in 2019.
Manu’s unique research perspective comes from combining a formal training in epidemiology and basic science (immunology). His translational research is deeply influenced by CA Janeway’s work on lymphocyte receptor diversity, and G Rose’s conceptual arguments entitled ‘Sick individuals and sick populations’, which is reflected in the research programme he leads on.His research explores ways to improve outcomes in adult critically ill patients with sepsis and with ARDS, by linking the illnesses’ immunobiology with novel interventional trial designs. His group has the following focussed research themes:
- Immunobiology: Explore adaptive immune system changes during sepsis, during ARDS and longer-term in patients who survive sepsis. They integrate orthogonal multilevel data with repeated measurements of cellular phenotype, functional assessments, alongside corresponding transcriptomes and epigenetic landscapes.
- Epidemiology and Stratified medicine: Manu’s work focuses on Treatable Traits principle. His group use data from randomised controlled trials with novel designs, cohort studies, systematic reviews and large clinical trial datasets to explore treatment effect heterogeneity; and to identify treatable traits based on dominant biological mechanisms in critically ill patients.
- COVID-19 research focuses on clinical trials, translational immunology and children with PIMS-TS illness: Translational immunology in adults focusing on how the immune system responses are influenced by treatment with convalescent plasma and recombinant interleukin-7 in the respective clinical trials.